NCCN Categories of Evidence and Consensus
Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.
Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.
All recommendations are category 2A unless otherwise noted.
Clinical trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Sleep disturbances include insomnia (trouble falling or staying asleep resulting in daytime dysfunction), excessive sleepiness (which can result from insufficient sleep opportunity, insomnia, or other sleep disorders), sleep-related movement or breathing disorders, and parasomnias.1 Sleep disorders affect 30% to 50% of patients with cancer and survivors, often in combination with fatigue, anxiety, or depression.1-10 Improvements in sleep lead to improvements in fatigue, mood, and quality of life.11 Most clinicians, however, do not know how best to evaluate and treat sleep disorders.1
Sleep disorders are common in patients with cancer as a result of multiple factors, including biologic changes, the stress of diagnosis and treatment, and side effects of therapy (eg, pain, fatigue).12 In addition, evidence suggests that changes in inflammatory processes from cancer and its treatment play a role in sleep disorders. These sleep disturbances can be perpetuated in the survivorship phase by chronic side effects, anxiety, depression, medications, and maladaptive behaviors such as shifting sleep times, excessive time in bed because of fatigue, and unplanned naps.12
Additional information about sleep disorders in patients with cancer can be found in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Palliative Care and the NCCN Guidelines for Cancer-Related Fatigue (available at NCCN.org). These guidelines may be modified to fit the individual survivor’s circumstances.
Ancoli-Israel S, Moore PJ, Jones V. The relationship between fatigue and sleep in cancer patients: a review. Eur J Cancer Care (Engl) 2001;10:245–255.
Carney S, Koetters T, Cho M et al.. Differences in sleep disturbance parameters between oncology outpatients and their family caregivers. J Clin Oncol 2011;29:1001–1006.
Flynn KE, Shelby RA, Mitchell SA et al.. Sleep-wake functioning along the cancer continuum: focus group results from the Patient-Reported Outcomes Measurement Information System (PROMIS®). Psychooncology 2010;19:1086–1093.
Forsythe LP, Helzlsouer KJ, MacDonald R, Gallicchio L. Daytime sleepiness and sleep duration in long-term cancer survivors and non-cancer controls: results from a registry-based survey study. Support Care Cancer 2012;20:2425–2432.
Zee PC, Ancoli-Israel S. Does effective management of sleep disorders reduce cancer-related fatigue? Drugs 2009;69 (Suppl 2):29–41.
Dirksen SR, Epstein DR. Efficacy of an insomnia intervention on fatigue, mood and quality of life in breast cancer survivors. J Adv Nurs 2008;61:664–675.
Palesh O, Aldridge-Gerry A, Ulusakarya A et al.. Sleep disruption in breast cancer patients and survivors. J Natl Compr Canc Netw 2013;11:1523–1530.
Omachi TA. Measures of sleep in rheumatologic diseases: Epworth Sleepiness Scale (ESS), Functional Outcome of Sleep Questionnaire (FOSQ), Insomnia Severity Index (ISI), and Pittsburgh Sleep Quality Index (PSQI). Arthritis Care Res (Hoboken) 2011;63(Suppl 11):S287–296.
- Search Google Scholar
- Export Citation
. Omachi TA Measures of sleep in rheumatologic diseases: Epworth Sleepiness Scale (ESS), Functional Outcome of Sleep Questionnaire (FOSQ), Insomnia Severity Index (ISI), and Pittsburgh Sleep Quality Index (PSQI). Arthritis Care Res (Hoboken) 2011; 63( Suppl 11): S287– 296.
Savard MH, Savard J, Simard S, Ivers H. Empirical validation of the Insomnia Severity Index in cancer patients. Psychooncology 2005;14:429–441.
Chung F, Yegneswaran B, Liao P et al.. STOP questionnaire: a tool to screen patients for obstructive sleep apnea. Anesthesiology 2008;108:812–821.
Silva GE, Vana KD, Goodwin JL et al.. Identification of patients with sleep disordered breathing: comparing the four-variable screening tool, STOP, STOP-Bang, and Epworth Sleepiness Scales. J Clin Sleep Med 2011;7:467–472.
Bassetti CL, Bornatico F, Fuhr P et al.. Pramipexole versus dual release levodopa in restless legs syndrome: a double blind, randomised, cross-over trial. Swiss Med Wkly 2011;141:w13274.
Ferini-Strambi L, Aarskog D, Partinen M et al.. Effect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trial. Sleep Med 2008;9:874–881.
Kaplan PW, Allen RP, Buchholz DW, Walters JK. A double-blind, placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene. Sleep 1993;16:717–723.
Manconi M, Ferri R, Zucconi M et al.. Pramipexole versus ropinirole: polysomnographic acute effects in restless legs syndrome. Mov Disord 2011;26:892–895.
Montplaisir J, Nicolas A, Denesle R, Gomez-Mancilla B. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology 1999;52:938–943.
Oertel WH, Stiasny-Kolster K, Bergtholdt B et al.. Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study). Mov Disord 2007;22:213–219.
Trenkwalder C, Garcia-Borreguero D, Montagna P et al.. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 2004;75:92–97.
Walters AS, Ondo WG, Dreykluft T et al.. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebocontrolled study. Mov Disord 2004;19:1414–1423.
Wilt TJ, MacDonald R, Ouellette J et al.. Pharmacologic therapy for primary restless legs syndrome: a systematic review and meta-analysis. JAMA Intern Med 2013;173:496–505.
Hornyak M, Scholz H, Kohnen R et al.. What treatment works best for restless legs syndrome? Meta-analyses of dopaminergic and non-dopaminergic medications. Sleep Med Rev 2013.
Morgenthaler T, Kramer M, Alessi C et al.. Practice parameters for the psychological and behavioral treatment of insomnia: an update. An American Academy of Sleep Medicine report. Sleep 2006;29:1415–1419.
Morgenthaler TI, Kapur VK, Brown T et al.. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep 2007;30:1705–1711.
Insomnia: assessment and management in primary care. National Heart, Lung, and Blood Institute Working Group on Insomnia. Am Fam Physician 1999;59:3029–3038.
Cheville AL, Kollasch J, Vandenberg J et al.. A home-based exercise program to improve function, fatigue, and sleep quality in patients with stage IV lung and colorectal cancer: a randomized controlled trial. J Pain Symptom Manage 2013;45:811–821.
Mishra SI, Scherer RW, Geigle PM et al.. Exercise interventions on health-related quality of life for cancer survivors. Cochrane Database Syst Rev 2012;8:CD007566.
Mishra SI, Scherer RW, Snyder C et al.. Exercise interventions on health-related quality of life for people with cancer during active treatment. Cochrane Database Syst Rev 2012;8:CD008465.
Mustian KM, Sprod LK, Janelsins M et al.. Multicenter, randomized controlled trial of yoga for sleep quality among cancer survivors. J Clin Oncol 2013;31:3233–3241.
Payne JK, Held J, Thorpe J, Shaw H. Effect of exercise on biomarkers, fatigue, sleep disturbances, and depressive symptoms in older women with breast cancer receiving hormonal therapy. Oncol Nurs Forum 2008;35:635–642.
Rogers LQ, Fogleman A, Trammell R et al.. Effects of a physical activity behavior change intervention on inflammation and related health outcomes in breast cancer survivors: pilot randomized trial. Integr Cancer Ther 2013;12:323–335.
Van Gerpen RE, Becker BJ. Development of an evidence-based exercise and education cancer recovery program. Clin J Oncol Nurs 2013;17:539–543.
Espie CA, Fleming L, Cassidy J et al.. Randomized controlled clinical effectiveness trial of cognitive behavior therapy compared with treatment as usual for persistent insomnia in patients with cancer. J Clin Oncol 2008;26:4651–4658.
Epstein DR, Dirksen SR. Randomized trial of a cognitive-behavioral intervention for insomnia in breast cancer survivors. Oncol Nurs Forum 2007;34:E51–59.
Gielissen MF, Verhagen S, Witjes F, Bleijenberg G. Effects of cognitive behavior therapy in severely fatigued disease-free cancer patients compared with patients waiting for cognitive behavior therapy: a randomized controlled trial. J Clin Oncol 2006;24:4882–4887.
Savard J, Simard S, Ivers H, Morin CM. Randomized study on the efficacy of cognitive-behavioral therapy for insomnia secondary to breast cancer, part I: sleep and psychological effects. J Clin Oncol 2005;23:6083–6096.
Nakamura Y, Lipschitz DL, Kuhn R et al.. Investigating efficacy of two brief mind-body intervention programs for managing sleep disturbance in cancer survivors: a pilot randomized controlled trial. J Cancer Surviv 2013;7:165–182.
National Institutes of Health. National Institutes of Health State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults, June 13-15, 2005. Sleep 2005;28:1049–1057.
Kim SW, Shin IS, Kim JM et al.. Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. Psychiatry Clin Neurosci 2008;62:75–83.